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The incidence of diabetes and the associated debilitating complications are increasing at an alarming rate worldwide. Current
therapies fortype 1 diabetes focus primarilyon administrationofexogenous insulinto help restore glucose homeostasis.However,
such treatment rarely prevents thelong-termcomplicationsofthisseriousmetabolic disorder, includingneuropathy, nephropathy,
retinopathy, and cardiovasculardisease. Whole pancreas or islet transplantationshave enjoyed limited success in someindividuals,
but these approaches are hampered by the shortage of suitable donors and the burden of lifelong immunosuppression. Here, we
review current approaches to diﬀerentiate nonislet cell types towards an islet-cell phenotype which may be used for larger-scale
cell replacement strategies. In particular, the diﬀerentiation protocols used to direct embryonic stem cells, progenitor cells of both
endocrine and nonendocrine origin, and induced pluripotent stem cells towards an islet-cell phenotype are discussed.
1.The Need forIslet Cell
ReplacementStrategies
The World Health Organisation (WHO) estimates that 220
millionpeoplesuﬀerfromdiabetesworldwide,whileapprox-
imately 3.4 million individuals died as a result of hypergly-
caemic complications in 2004. Administration of exogenous
insulin is the fundamental means of treating hyperglycaemia
in type 1 diabetes, but it does not restore the physiological
regulation of blood glucose. Additionally, patients with
poorly controlled type 2 diabetes are increasingly being pre-
scribedinsulin therapy,with studiessuggesting that intensive
insulin therapy even in newly diagnosed type 2 diabetes can
improve beta-cell survival and function compared with oral
hypoglycaemic agents [1]. However, tight glycaemic control,
withitsinherentriskofhypoglycaemia,isrequiredtoprevent
many of the long-term complic a t i o n so fd i a b e t e si n c l u d -
ing cardiovascular disorders, nephropathies, and diabetic
retinopathy. WHO ﬁgures show that 50% of people with
diabetes die of cardiovascular disease, while kidney failure
accounts for 10–20% of deaths. Given these shortcom-
ings, recent research has been directed towards establishing
cellular-based therapies that avoid the need for exogenous
insulin delivery by conventional injection or more modern
pump technology (see the study by Cohen and Shaw [2]).
Arguably one of the most attractive of these strategies
involves replacement of insulin-producing islet-cells by
transplantation therapy [3, 4]. The ﬁrst successful transplan-
tation of isolated pancreatic islets was conducted in rodents
byBallingerandLacyin1972[5].Althoughthisstudyoﬀered
hope that a cure for diabetes was possible, four decades later,
islet transplantation in humans is not commonplace. The
lack of fresh viable donor material coupled with problems of
immunocompatability and life-long immunosuppression to
prevent graft rejection has made the widespread application
of both techniques almost impossible [3, 4, 6].
Stem cells are found in multicellular organisms and
have the potential to diﬀerentiate into a variety of diﬀerent
cell types. Stem cells are largely divided according to their
potency or ability to diﬀerentiate. Totipotent stem cells may
generateany somatic orgermlinecell, while pluripotentstem
cells may give rise to cells originating from any of the three
germlayers:endoderm,mesoderm,orectoderm.Thecurrent
paper examines advances in the ﬁeld of stem cell therapy for
the treatment of diabetes and outlines the varied approaches
that have been used to create insulin-producing cells. In2 Stem Cells International
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Figure1:Regulationofpancreaticdevelopment.(a)Pancreaticcells(bothendocrineandexocrine)originatefromthesamePdx-1expressing
endodermal cells. The transcription factor Ngn3 is required for diﬀerentiation into an endocrine phenotype. Further development into
insulin-, glucagon-, or somatostatin-secreting cells is tightly regulated by a range of transcription factors as indicated in the ﬁgure. Pax,
NKX, Pdx-1, and Brn4 are homeodomain proteins which are generally involved in morphogenesis, while MafA and MafB are members of
the large Maf protein family which regulates pancreatic development. (b) Timescale showingemergence of islet hormone-producing cells in
the rodent embryo.
particular, the exploitation of developmental biology path-
ways, which are brieﬂy outlined in the following, to direct
embryonic stem cells (ESCs) towards an insulin-producing
phenotype is examined. Alternative approaches including
the use of pancreatic adult stem cells, islet progenitor cells
of both endocrine and nonendocrine origin, and induced
pluripotent stem cells are also considered.
2.Developmentof theEndocrinePancreas
The pancreas is formed during embryogenesis from fusion
of the dorsal and ventral primordia and has both exocrine
and endocrine functions [7]. The transcriptional regulation
of pancreas diﬀerentiation is shown in Figure 1. The adult
human pancreas is comprised of approximately 1 million
islets of Langerhans that form the endocrine portion of
the gland, constituting 2-3% of the total pancreatic mass
[8]. Acinar and ductal tissues largely comprise the exocrine
pancreas. Islets are anatomically complex microorgans com-
prisedofheterogenouscelltypesthatsecreteinsulin fromthe
beta-cell, glucagon from the alpha-cell, somatostatin from
the delta-cell, and pancreatic polypeptide (PP) from PP cells
[8].
Duringdiﬀerentiationoftheendocrinetissue,progenitor
cells coexpress various endocrine hormones prior to ﬁnal
maturation into cells expressing a single hormone [7].
In rodent models, the ﬁrst endocrine cells detected are
glucagon-secreting cells which are evident from approx-
imately embryonic day 9.5 [9, 10]. This is followed by
the presence of insulin-producing cells which coexpress
glucagon, while fully diﬀerentiated insulin-releasing beta-
cells and glucagon-secreting alpha-cells are observed from
day14.Somatostatin-secreting delta-cellsdevelopsoonafter-
wards, while PP-releasing cells are observed shortly before
the end of gestation at approximately day 18 when clustering
of cells to form islets is also observed [9, 10].
All endocrine cells originate from pancreatic and duo-
denal homeobox 1 (Pdx-1) expressing progenitor cells
(see Figure 1). During pancreatic development, Pdx-1 is
expressed in both endocrine and exocrine progenitors, but,
in the developedpancreas, Pdx-1 is generally observed in the
beta-cellsanddelta-cells[11].Thedevelopmentofendocrine
cells is regulated by the basic helix-loop-helix (bHLH) tran-
scription factor Neurogenin 3 (Ngn3), with the inhibition of
Ngn3 in the pancreas at embryonic day 11.5 resulting in a
signiﬁcant reduction in endocrine diﬀerentiation [12]. The
further development of speciﬁc islet hormone-expressing
cells is regulated by an additional range of transcription
factors [13]. In particular, beta-cell diﬀerentiation is largely
regulated by NK2 homeobox 2 (NKX2.2) [14]. For a more
complete review of pancreatic development, please see the
study by Kordowich et al. [15].Stem Cells International 3
3.EndocrineProgenitorCellsand
Beta-CellReplication
Ngn3 is essential for the development of all endocrine cells
from Pdx-1-positive progenitors [13]. Ngn3 null mice lack
pancreatic islets and die of hyperglycaemia shortly after
birth[13].Althoughgenerallyassociatedwiththedeveloping
pancreas, it has been shown that adult islet cells express low
levelsofNgn3andthatthismayplayaroleinregulatingbeta-
cell replication [16].
Beta-cells are capable of responding to changing phys-
iological requirements including pregnancy and obesity
which are associated with an increase in beta-cell mass and
insulin secretion [8, 17]. Animal studies have shown that
beta-cells self-duplicate (see review by Gonez and Knight
[18]), although the mechanisms behind this process are
poorly understood. Various compounds have been shown
to enhance beta-cell proliferation and mass. Most notably,
treatment with gastrin and epidermal growth factor (EGF)
has been shown to evoke signiﬁcant improvements in the
number of insulin-producing cells present [19]. However,
the eﬀects of such treatment are transient and short-lasting.
Therefore, the therapeutic use of beta-cells to create other
beta-cells is complicated and unlikely to be applicable on a
long-term basis in vivo.
The regeneration of beta-cells by existing beta-cells
takes place in association with pancreatic ductal cells [20].
However, debate exists as to whether ductal cells are true
progenitors for the development of pancreatic beta-cells. A
recent study labeled pancreatic ductal cells following duct
ligation in mice and concluded that these labeled cells
diﬀerentiated into beta-cells after 4 weeks [21]. Similar
studies have conﬁrmed this result [22]. However, as a note of
caution, other work contradicts these ﬁndings and suggests
that ductal cells contribute to beta-cell neogenesis before,
but not after, birth [23, 24] .T h ep r e s e n c eo ft r u ee n d o c r i n e
progenitors in the adult pancreas is, therefore, highly debat-
able, and many argue that the relative lack of constitutive
Ngn3 expression in adult endocrine cells would suggest
that beta-cell neogenesis originates from existing beta-cells.
However, work by Finegood and colleagues showed that
the rat pancreas was able to regenerate even after extreme
conditions of 90% pancreatectomy and pretreatment with
the beta-cell toxin streptozotocin [25]. This would suggest
that beta-cells are not the only source of beta-cell neogenesis
in the adult islet. Moreover, treatment of pancreatic ductal
cells with Glucagon-like peptide 1 (GLP-1) enhances beta-
cell proliferation and reduces apoptosis, in vivo and in vitro
[26]. Activation of the GLP-1 receptor is thought to improve
islet neogenesis by upregulating Pdx-1 expression in ductal
progenitor cells and may, therefore, prove useful in future
regenerative therapies [26].
The junction between the ductal epithelium and adja-
cent acinar cells houses centroacinar/terminal ductal cells
(CA/TD), which lack many markers of diﬀerentiated
endocrine cells [27]. However, these cells are positive for
progenitor cell transcripts including nestin and Sox9 [27].
Rovira and colleagues have recently shown that CA/TD
cells are capable of spontaneously developing into endocrine
or exocrine phenotypes and retain glucose-induced insulin
secretion. Moreover, it was suggested that these cells con-
tribute to the preservation of tissue homeostasis in the
murine pancreas [27].
4.Directed Differentiationof
Nonendocrine Progenitors
G i v e nt h ec o m m o no r i g i no ft h el i v e ra n dp a n c r e a sa n d
shared progenitor cells, the liver has been examined as an
alternative source of islet progenitor cells. Under normal
circumstances hepatocytes are able to regenerate and prolif-
erate; however, chemical inhibition of this process results in
the production of a liver progenitor cell population which
is referred to as oval cells [28]. Oval cells share common
features of pancreatic progenitor cells and may be directed
towards an insulin-producing phenotype under appropriate
culture conditions [29], including culture in high-glucose
medium [30]. Hepatic expression of the Pdx-1 gene in the
liverofstreptozotocin-induceddiabeticmicehasbeenshown
to result in the presence of insulin-positive cells in the liver
[31, 32]. However, this approach has been limited ﬁrstly, by
the toxicity associated with adenoviral delivery of the Pdx-
1g e n e[ 31] and, secondly, by the high level of mortality
associated with Pdx-1 expression in the liver which lead to
hepatic dysmorphogenesis [33] and autodigestion of hepatic
cells which coexpressed exocrine enzymes and insulin [32].
Inanattempttoovercomethiscomplication,Kojimaand
colleagues used a transcription factor located downstream
of Pdx-1 called B2/NeuroD to induce the neogenesis of
islet cells expressing all four major islet hormones in the
liver [32]. In a similar vein, the adenoviral delivery of
Ngn3 in combination with a beta-cell growth factor called
betacellulin to the liver of streptozotocin-induced diabetic
mice resulted in the production of islet-like cells releasing
insulin, glucagon, somatostatin, and pancreatic polypeptide
[34]. In both studies, the resulting islet-like cells were
reported to display glucose-stimulated insulin secretion and,
following in vivo transplantation, reversed streptozotocin-
induced diabetes for extended periods of time. Importantly,
the beta-like cells derived following viral transfection of
Ngn3 and betacellulin were found to originate from liver
oval cells by lineage tracing [32, 34]. Very recently, it was
found that transcription factors found in adult pancreatic
cells, most notably NKX6.1, which has been shown to be
essential in alpha- and beta-cell development in a variety of
organisms [35–37], promotes Pdx-1-induced liver to beta-
cell reprogramming, and such approaches may provide an
alternative means of directing hepatic cells to a beta-cell
phenotype [38].
5.GenerationofIslet Cellsfrom
Embryonic StemCells(ESCs)
The recent FDA approval of the ﬁrst clinical trial using
human ESC in the United States has brought with it
renewed conﬁdence that stem cell-based therapies may
become clinically tested. Given their pluripotent nature,4 Stem Cells International
ESCs were traditionally viewed as being a highly attractive
source of material which could be diﬀerentially directed
towards speciﬁc islet cell types by following established
developmental pathways. However, the production of a
single islet hormone-secreting or -expressing cell remains
diﬃcult.
ESCs are isolated from the inner cell mass of a blastocyst.
In this undiﬀerentiated state, it has been reported that
embryonic stem cells may express insulin naturally [39].
Cells containing the insulin gene may then be selected
and directed towards a beta-cell phenotype through various
culture conditions. Soria and colleagues were the ﬁrst to
clone insulin-secreting cells from undiﬀerentiated ESCs via
a “cell-trapping” technique [39]. This technique is based
on the principle that a greater yield of diﬀerentiated cells
will be obtained when a genetic marker is used. In this
instance, ESCs are transfected with a chimeric construct
which couples the insulin gene with a gene that confers
drug resistance (i.e., neomycin). Therefore, cells which
express the protein of interest (i.e., insulin) will also be
positive for the neomycin resistance gene [39]. These cells
displayed regulated insulin secretion in response to various
secretagogues in vitro, while clusters of these clones were
able to reverse hyperglycaemia induced by streptozotocin in
mice. The cell-trapping technique was found to obtain a
relatively pure population of insulin-positive cells expressing
the beta-cell markers Pdx-1, Nkx6.1, insulin, glucokinase,
glucose transporter 2 (GLUT-2), and Sur-1 [39]. However,
theproductionoffunctionalbeta-cellscapableofresponding
exclusively to glucose was not achieved.
An alternative approach developed by Lumelsky and
colleagues involves the production of insulin-secreting cells
fromESCsderivedfromcoloniesofnestin-positiveembryoid
bodies [28]. Nestin is expressed in the embryo in developing
neurons. Neural and islet cells share phenotypic similarities,
and, therefore, nestin-positive cells are selected with the aim
of diﬀerentiating towards an islet cell phenotype [40]. Fol-
lowinga novelﬁve-stagediﬀerentiationprocess, theresulting
insulin-producing cells were able to self-form clusters that
were reported to be anatomically similar to rodent islets in
vivo [28]. Further adaptations of this protocol showed that
glucose-dependent insulinotropic peptide (GIP) treatment
aided the diﬀerentiation process [41]. However, these cells
also coexpressed other islet hormones, and concerns have
been raised as to whether the altered culture conditions
detailed in the protocol are suﬃcient to achieve a true beta-
cell phenotype [42–45]. The detection of de novo insulin
secretion from these diﬀerentiated stem cells has also proved
diﬃcult arising from the inherently high proportion of
insulin added to the culture medium [45].
Subsequent studies have focused on altering culture
conditions or diﬀerentiation process to produce insulin-
secreting cells from rodent ESCs. Culturing mouse ESCs
with inhibitors of phosphoinositide 3-kinase, an essential
intracellular signaling regulator, yielded cells that resembled
pancreatic beta-cells and which rescued glycaemic control in
diabetes mice [46]. The regulated expression of Pdx-1 was
alsoshowntoaidinvitrodiﬀerentiationofinsulin-producing
cells from ESCs [47]. Furthermore, it was shown that Pax4
overexpressing ESCs showed signiﬁcant improvements in
Ngn3, insulin, islet amyloid polypeptide, and Glut-2 mRNA
levels [48]. Despite these improvements in culture models
and diﬀerentiation processes, the production of a mature
and glucose-responsive beta-cell from ESCs remains elusive.
A summary of the culture conditions and diﬀerentiation
processes used to generate insulin-secreting cells from ESC
is given in Table 1.
The ESC studies described thus far have concentrated
on the use of undiﬀerentiated or partially diﬀerentiated
ESCs [16–22]. Clinically, however, the use of partially
diﬀerentiated cells is limited by the possibility of tumour
formation. Rezania and colleagues sought to address this
issue by developing a diﬀerentiation protocol utilizing
feeder- and serum-free conditions to diﬀerentiate human
ESCs into glucagon-secreting cells that resemble mature
alpha-cells [49]. During early stages of the diﬀerentiation
process, the cells were reported to coexpress glucagon
and insulin. However, subsequent culture stages saw the
reduction of beta-cell markers and fortiﬁcation of alpha-
cell characteristics including responsiveness to arginine [49].
Moreover,transplantationofthesecellsresultedintherelease
of fully processed and biologically active glucagon following
fasting and amino acid stimulation [49]. It is hoped that
this protocol may be further developed in order to produce
mature beta-cells from ESCs.
6.Induced PluripotentStemCellsfor
Islet Cell Generation
The directed reprogramming of somatic cells into a pluripo-
tent phenotype is referred to as induced pluripotency and is
outlined in Figure 2. In practice, this generally involves the
forced expression of speciﬁc factors including, for example,
transcription factors [50]. The resultant induced pluripo-
tent stem cells (iPSCs) share common features with ESCs
including high telomerase activity and hypomethylation of
gene promoters [51, 52] but may be seen as preferable to
ESCs as iPSCs can be patient speciﬁc, thereby, removing the
likelihood of rejection.
RecentlytheconversionofiPSCsoriginatingfromﬁbrob-
lasts to pancreatic beta-like cells was achieved through a
three-stage diﬀerentiation process [53]. Initially, embryoid
bodies were formed from a single cell suspension of
iPSC. Subsequently, the embryoid bodies were returned to
adherent cultures and allowed to undergo further sponta-
neous diﬀerentiation [53]. The ﬁnal stage involved directed
diﬀerentiation in medium supplemented with laminin,
insulin, and nicotinamide [53]. These cells shared many
transcripts with native beta-cells including insulin, islet
amyloid polypeptide, and Pdx-1. Furthermore, transplan-
tation of these cells into diabetic mouse model provided
long-term correction of hyperglycaemia with attainment of
normal haemoglobin (Hb) A1c levels [53]. An additional
study by Zhang and colleagues employed identical culture
protocolstodiﬀerentiatehumanESCsandiPSCsintomature
pancreatic insulin-producing cells [54]. iPSCs were induced
from human ﬁbroblasts into Pdx-1 expressing progenitorStem Cells International 5
Table 1: Summary of approaches used to diﬀerentiate embryonic stem cells to insulin-producing cells.
Origin Diﬀerentiated from Markers Ref.
1M o u s e Embryoid bodies (Hanging Drop
Technique)
Pdx, Nkx6.1, insulin, GLUT2,
glucokinase, SUR1
[39]
2M o u s e Embryoid bodies Nestin, Pdx1, Nkx6.1, Oct4, insulin,
glucagon
[28]
3M o u s e Embryoid bodies (addition of GIP to
culture medium)
Nestin, Pdx1; Nkx6.1, Pct4, insulin,
g l u c a g o n ,G L U T 2 ,S U R 1 ,K i r 6 . 2 ,G L P - 1 R
[41]
4H u m a n Deﬁnitive endoderm GSC, SOX17, FOX2A [64]
5H u m a n Embryoid bodies (use of knock-out
serum replacement)
Maf6, Nkx6.1, Isl-1; NeuroD, Pdx-1,
GLUT2, insulin, C-peptide
[53]
Induced pluripotent
stem cell
Somatic
cell
Pancreatic
beta-cell
Diﬀerentiation
Reprogramming
Embryonic
stem cell
Diﬀerentiation
Reprogramming
Diﬀerentiation Reprogramming
Figure 2: Directed diﬀerentiation of embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs) towards a beta-cell
phenotype. ESCs are derived from the inner cell mass of the
blastocyst and have the potential to develop into any somatic cell
lineage. Studies haveshown thatESCs can be diﬀerentiated towards
a beta-cell phenotype which releases insulin in response to stimuli
including glucose. iPS cells are derived as a result of the directed
reprogramming of somatic cells into a pluripotent phenotype. This
generally involves the forced expression of a gene or transcription
factor. iPSCs can be used to generate beta-like cells, while beta-cells
themselves can be used to produce iPSCs for further expansion of
the beta-cell population.
cells before ﬁnal diﬀerentiation towards an insulin-secreting
phenotype. The diﬀerentiated cells were positive for Pdx-1,
MafA, GLUT2, insulin, and C-peptide [54]. These ﬁndings
may open the possibility of using patient-speciﬁc iPSCs for
cell replacement therapies in diabetes.
Interestingly, it has also been found that adult pancre-
atic beta-cells can be reprogrammed into iPSCs [55, 56].
Lentivirusesexpressing thepluripotencymarkersOct4,Sox2,
c-myc, and Klf4 were introduced into tagged mature beta-
cells, and their development was followed. It was found that
transfected beta-cells produced iPSCs that were positive for
markers ofpluripotencyandgaverisetoavarietyofcelltypes
of all germ layers in chimeric animals [55]. This observation
has been replicated using ﬁbroblasts from patients with type
1 diabetes, which were induced to pluripotency and onwards
to an insulin-secreting cell type [56].
While iPSCs oﬀer great hope for stem cell-based thera-
pies, the potential complicationsof this approach should not
be overlooked.Recently,Listeret al.report thatiPSCsdisplay
signiﬁcant variations in reprogramming. Importantly, the
diﬀerentiation of iPSCs to trophoblasts caused signiﬁcant
changes inDNAmethylation thatwere maintained evenafter
full diﬀerentiation has been completed [57].
7.FuturePerspectives
Signiﬁcant advancements have been made in the con-
version of nonislet cells to islet hormone-secreting cells.
The majority of research has focused on the conversion
of non-beta-cells to beta-cells in an attempt to provide
cellular transplants aﬀording insulin secretion, and ideally
glucose responsiveness, for the tight control of diabetes.
Given the observations that homotypic cells interactions are
suﬃcient to maintain normal patterns of insulin secretion
[58–60], the production of pure beta-cell populations from
ESC, progenitor cells, or iPS may well prove suﬃcient to
restore glucose homeostasis. However, at present, an ESC-
based approach to beta-cell generation is complicated by
the heterogenous nature of the diﬀerentiated cells which
express all four major islet hormones and lack of de novo
insulin secretion [21, 22]. Furthermore, the unacceptable
risk of teratoma formation [61] means that the therapeutic
application of ESC-derived islet cells is unlikely at least in
the near future. As such, further focus on feeder-free culture
systems is required and may improve the likelihood of ESC-
based therapies for the treatment of diabetes.
Initial studies on the use of endocrine and nonendocrine
progenitor cells to produce insulin-secreting populations
have proved promising. However, an incomplete under-
standing of the transcriptional regulation and debate over
what constitutes a true islet progenitor as well as how beta-
cellsreplicateandproliferatehasmadetheseﬁndingsdiﬃcult
to interpret in terms of their suitability for therapeutic
application. Recent work on iPSC has oﬀered more hope
for the development of a cell replacement therapy for
diabetes. Moreover, there isa growing ﬁeld ofresearch on the6 Stem Cells International
directed diﬀerentiation of mesenchymal stem cells (MSCs)
towards a beta-cell phenotype. While MSC populations are
less expandable than ESC or iPS populations, they may be
obtained frombone marrow oradipose tissue and, therefore,
may be derived from the recipient and thus should alleviate
the need for immunosuppression. A great deal of time and
investmentiscurrentlybeingplacedonnewmethodstotrack
and monitor the viability of stem cells after transplantation.
These include in vivo imaging techniques and cell labeling as
reviewed in detail by Rodriguez-Porcel [62]. These advances
will greatly aid with stem cell-based therapies for a host of
diﬀerent disorders.
Despitetheshortcomings associated with stem cell-based
approaches for islet-cell generation, the need for a genuine
cell replacement therapy for diabetes persists. The incidence
of diabetes is rapidly increasing worldwide, warranting a
range of approaches to tackle this life-threatening condi-
tion. The administration of exogenous insulin and incretin
mimetics (see review by Irwin and Flatt [63]) can certainly
alleviate hyperglycaemia in type 1 and poorly controlled
type 2 diabetes. However, these therapeutic approaches do
not oﬀer an ideal long-term solution, and strict adherence
to treatment regimes and regular glucose monitoring are
required to prevent many of the devastating long-term
complications of diabetes. Islet and whole pancreas trans-
plantations are not a realistic large-scale solution. Therefore,
thedirecteddiﬀerentiationofnonisletcelltypesmayoﬀerthe
only large-scale alternative to produce a viable cure. While
the current protocols require development, this research
ﬁeld is still in its infancy and is rapidly expanding with
new developments appearing on almost a monthly basis.
Moreover, the rapid advances in molecular and cellular
biology provide the continual promise of exciting new
mechanistic insights into cell development, diﬀerentiation,
and survival. Accordingly, stem cell-based approaches oﬀer
great potential for the future and, with perseverance, may
ultimately provide a cure for diabetes [64].
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